🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Solara Active Pharma Sciences Limited SOLARA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.solara.co.in
Company Profile ↓
₹576.65
-7.16% 1Y
Mkt Cap₹2,777.81 Cr
P/E-343.24
P/B2.04
52W High₹697.00
52W Low₹425.55
Book Value₹260.09
EPS (TTM)₹-1.68

Company Overview

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 22.2% per year over the last five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,368.98 Cr (+6.6% YoY); net profit ₹-7.41 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.6%, earnings -1472.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR -0.2%, profit CAGR 22.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-0.25%
1 Year:6.64%

Compounded Profit Growth

5 Years:22.20%
1 Year:-1,472.22%

Stock Price Performance

1 Year:-7.16%
6 Months:+5.28%
3 Months:+17.32%
1 Month:-4.08%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 56% of range
₹425.55 ₹697.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)54.41 · Neutral
Price Performance
1M-4.08%
3M+17.32%
6M+5.28%
1Y-7.16%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 22.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-343.24
Industry PE
39.97
Forward P/E
18.36
PEG Ratio
-
Book Value
₹260.09
Price to Book
2.04
P/S
2.06
EV/EBITDA
17.08
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-0.25%
Profit 5Y
22.20%
Revenue (YoY)
6.64%
Earnings (YoY)
-1,472.22%

Profitability & Returns

ROCE
6.07%
ROE
-0.59%
ROA
-0.32%
Profit Margin
-0.54%
Op Margin
6.36%
Gross Margin
50.00%
EPS (Latest Qtr)
₹2.20
EPS (TTM)
₹-1.68

Balance Sheet & Liquidity

Debt/Equity
0.55
Quick Ratio
0.60
Current Ratio
0.96
Debt
₹686.56 Cr
Total Assets
₹2,332.59 Cr
Current Assets
₹858.10 Cr
Working Capital
₹-35.81 Cr

Ownership

Promoter Holding
53.30%
Chg in Prom Hold
-0.01%
FII / Inst Holding
16.77%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹2,777.81 Cr
Total Revenue (TTM)
₹1,368.98 Cr
EBITDA
₹187.02 Cr
Free Cash Flow
₹100.09 Cr
Operating Cash Flow
₹152.91 Cr
Shares Outstanding
₹4.82 Cr
Gross Margin
50.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SOLARA Solara Active Pharma Sciences Limited NSEPHARMA 576.65 -343.24 ₹2,777.81 Cr 0.00% 6.07% -0.59% -0.25% 22.20%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 380.62 Cr352.31 Cr425.24 Cr211.94 Cr299.43 Cr363.49 Cr--273.01 Cr319.15 Cr313.54 Cr349.00 Cr387.29 Cr
Cost of Revenue --------118.09 Cr146.47 Cr154.00 Cr186.60 Cr197.44 Cr
Gross Profit --------154.92 Cr172.68 Cr159.54 Cr162.40 Cr189.85 Cr
Operating Expenses 331.85 Cr333.19 Cr387.61 Cr373.63 Cr289.67 Cr321.57 Cr--133.85 Cr139.24 Cr149.30 Cr150.63 Cr158.23 Cr
Operating Income 22.32 Cr-6.79 Cr11.42 Cr-187.65 Cr-15.49 Cr16.85 Cr--21.07 Cr33.44 Cr10.24 Cr11.77 Cr31.62 Cr
EBITDA 48.77 Cr19.12 Cr37.63 Cr-161.69 Cr9.76 Cr41.92 Cr--51.32 Cr58.00 Cr35.22 Cr30.59 Cr63.21 Cr
Interest Expense 21.96 Cr24.61 Cr24.44 Cr25.37 Cr30.69 Cr30.87 Cr--29.12 Cr23.90 Cr20.83 Cr22.45 Cr27.57 Cr
Pretax Income 5.04 Cr-29.36 Cr-17.06 Cr-275.34 Cr-166.66 Cr-13.46 Cr---2.10 Cr10.52 Cr-10.10 Cr-17.43 Cr9.60 Cr
Tax Provision 1.28 Cr10.25 Cr-0-0-88.80 Cr-0--00000
Net Income 3.76 Cr-19.11 Cr-17.06 Cr-275.34 Cr-255.45 Cr-13.46 Cr---2.10 Cr10.52 Cr-10.10 Cr-17.43 Cr9.60 Cr
Diluted EPS 0.79-4.07-3.58-57.36-53.20-3.74---0.932.46-2.36-3.982.20

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 521.00 Cr1,387.00 Cr1,322.00 Cr1,617.00 Cr-1,379.19 Cr1,238.39 Cr1,283.76 Cr1,368.98 Cr
Cost of Revenue -----813.22 Cr838.51 Cr626.41 Cr684.51 Cr
Gross Profit -----565.97 Cr399.88 Cr657.35 Cr684.47 Cr
Operating Expenses 464.00 Cr1,174.00 Cr1,062.00 Cr1,231.00 Cr-532.81 Cr597.96 Cr550.32 Cr597.40 Cr
Operating Income 23.00 Cr130.00 Cr166.00 Cr277.00 Cr-33.16 Cr-198.08 Cr107.03 Cr87.07 Cr
EBITDA 57.00 Cr213.00 Cr260.00 Cr386.00 Cr-149.75 Cr-285.27 Cr214.60 Cr187.02 Cr
Interest Expense 25.00 Cr82.00 Cr78.00 Cr84.00 Cr-83.38 Cr99.82 Cr114.81 Cr94.75 Cr
Pretax Income 060.00 Cr115.00 Cr222.00 Cr--44.82 Cr-488.42 Cr54.00 L-7.41 Cr
Tax Provision -060.00 L00--22.57 Cr78.54 Cr00
Net Income 059.00 Cr115.00 Cr221.00 Cr--22.18 Cr-567.39 Cr54.00 L-7.41 Cr
Diluted EPS -17.3032.0146.22--5.68-148.510.14-1.68

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,821.00 Cr1,960.00 Cr2,153.00 Cr2,614.00 Cr-2,899.28 Cr2,350.96 Cr2,231.84 Cr2,332.59 Cr
Current Assets -----1,187.54 Cr800.75 Cr728.73 Cr858.10 Cr
Cash & Equivalents -----8.73 Cr8.44 Cr3.95 Cr4.48 Cr
Inventory -----558.09 Cr359.70 Cr317.90 Cr317.87 Cr
Receivables -----536.99 Cr348.52 Cr326.57 Cr438.72 Cr
Total Liabilities -----1,396.83 Cr1,414.38 Cr1,134.93 Cr1,077.04 Cr
Current Liabilities -----1,101.13 Cr1,242.85 Cr944.11 Cr893.91 Cr
Long Term Debt -----235.10 Cr105.83 Cr113.86 Cr110.45 Cr
Total Debt 633.00 Cr538.00 Cr722.00 Cr621.00 Cr-1,012.85 Cr1,011.50 Cr796.08 Cr686.56 Cr
Total Equity 764.00 Cr956.00 Cr1,086.00 Cr1,589.00 Cr-1,500.21 Cr933.91 Cr1,094.24 Cr1,252.88 Cr
Shares Outstanding -----3.91 Cr3.91 Cr4.81 Cr4.82 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 49.00 Cr166.00 Cr242.00 Cr155.00 Cr-156.25 Cr108.87 Cr212.82 Cr152.91 Cr
Investing Cash Flow -85.00 Cr-113.00 Cr-359.00 Cr-106.00 Cr--81.14 Cr-3.51 Cr-36.83 Cr-98.83 Cr
Financing Cash Flow 68.00 Cr-23.00 Cr97.00 Cr92.00 Cr--112.76 Cr-105.65 Cr-180.48 Cr-53.55 Cr
Capital Expenditure -35.00 Cr-58.00 Cr-267.00 Cr-171.00 Cr--111.31 Cr-41.06 Cr-39.94 Cr-52.82 Cr
Free Cash Flow 14.00 Cr108.00 Cr-25.00 Cr-16.00 Cr-44.94 Cr67.81 Cr172.88 Cr100.09 Cr
Net Change in Cash 31.00 Cr30.00 Cr-20.00 Cr142.00 Cr--37.65 Cr-29.00 L-4.49 Cr53.00 L

Ratios (Annual)

Figures in %.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -----41.0%32.3%51.2%50.0%
Operating Margin % 4.4%9.4%12.6%17.1%-2.4%-16.0%8.3%6.4%
Net Margin % 0.0%4.3%8.7%13.7%--1.6%-45.8%0.0%-0.5%
ROE % 0.0%6.2%10.6%13.9%--1.5%-60.8%0.0%-0.6%
ROCE % -----1.8%-17.9%8.3%6.1%

Shareholding Pattern

Insiders
53.30%
Institutions
16.77%
Public Float
35.92%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SOLARA

Google News Wed, 10 Dec 2025

Solara Active Pharma Sciences Limited (NSE:SOLARAPP1) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxPSjQ0Mm05WUd1YUxhQ1VRb1c4SGpXS21iQVNpdURmWUZDQ0tTajl1ekNIeEprZjg4MzdwWXRNTVAwc2I4T0NDbjU3eTNkQlg0emR4OHUtZ0lVaDdqR3JBTXhGc210ZzJZSEdYbHk1VWZYT3U5M1paR25GaFdCMmFSZ2RHbzdkOFpWTExzU0…

Google News Fri, 15 May 2026

Solara Active Q4 Results: Stock jumps 15% after profitability returns, revenue growth - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxOVTgzQjZfTEx3MkRIclhtdUhuejNjNHdBRVdJTEltakF0WllMcGNGWC1sWDd2WDRJS2JjcmxVOFhzSDNxYi00cHRiRmdfeHo0aURyd1VGOEoxaHRJdHBlcDNMeDNpRkE2aXltdzRrRjRRSEJhT1BTeHZtaEZpYm0wVDVCYXZLa0RSTVIyYm…

Google News Fri, 15 May 2026

Solara Active Pharma spurts after reporting turnaround Q4 perfromance - Business Standard

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNai1Dd1NiSkhPaEVPZTlUcmZUNTNDV0w1a0luSk5WYVFxZ01aVEh6YWl1dXQtbUJYUmxKLVYyMW1EWEdoWmJfc1A5d1Njcmt1VmlYaTQxLTVTWlF4RDVfQmhRaldjNndDclprRlEzT2JmM3JFQ0VoZ01tWlJiMm5taXJaYjJVZ3ZOVDJpaF…

Google News Fri, 15 May 2026

Solara shares jump over 14% after pharma giant posts ₹9.6 crore Q4 profit vs net loss; revenue up 42% YoY - Upstox

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxQNXM0RkN2U29uN3lrV0lHdUZkNUVHZE1CQUJBdE9HZDdTMlVEanVxejFsRlBrUzh4UjhoZmZSNmxwU0JNVnV1R1pPcHBTNlpYSWxCTzN5aVBFYnRoNkZwR1RFY2FQNHEyVnRTd3FxX3pDdmN3em91TWowY2ZmMXZVRjhnZWlNU0ZlVjhhN0…

Google News Fri, 05 Jun 2026

Can Solara Minerals (ASX: SLA) Build on Its Latest Share Price Gain? - Kalkine

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPR1gxSkhhYWdNV3REdGhJNHl4Y0ZWaTUxSkY4MGo2V2lpeEdVNlFib3pnMnRVTXd4UUlETjN0YXZpcC05MVE5OXZpZi1VNjRmNUl5R1pNLU13Q21uQkxjTHJtd2NGZ08wa09mY1ZFek82TXN2LTB6eEhYa0l3UHBNU2U3OFdRX0UzSDZzS2…

Google News Wed, 29 Apr 2026

9 Stocks to watch: Vedanta, RVNL, BHEL, OneSource, Wanbury, Solara Active, Adroit Infotech - BusinessLine

<a href="https://news.google.com/rss/articles/CBMirgJBVV95cUxPa05BQlNzTU44N2dwa2stdi0wWmdfamZxUmtDTjJFRkc4bW0wWmh5Zm9Dd3FabU9tZGd6V09pTUlIT2VkOXRBdWg3dmwwM0RTUm1CX1BPZjhidEZTcTNZWjdHcjBSMmFBNmJIU2dSeXlhZ29ZZEs4amEzVVkzSWtkUkxROTBpYmRNN0FoTE…

SOLARA — Frequently Asked Questions

What is the current share price of Solara Active Pharma Sciences Limited (SOLARA)?

As of 2026-07-15 09:52 IST, Solara Active Pharma Sciences Limited (SOLARA) trades at ₹576.65 on NSE. Its 52-week range is ₹425.55 to ₹697.00.

What is the market capitalisation of SOLARA?

Solara Active Pharma Sciences Limited (SOLARA) has a market capitalisation of ₹2,777.81 Cr on NSE.

What is the P/E ratio of SOLARA?

SOLARA trades at a trailing price-to-earnings (P/E) ratio of -343.24. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.04.

What is the return on equity (ROE) of SOLARA?

SOLARA has a return on equity (ROE) of -0.59%. Its return on capital employed (ROCE) is 6.07%.

Is SOLARA a good stock to buy?

This page provides a data-driven analysis of Solara Active Pharma Sciences Limited (SOLARA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space